The meta-analysis supports the use of EGFR mAbs in the treatment of mCRC without mutations in KRAS, particularly for left-sided colorectal cancer and where the tumour does not harbour NRAS or BRAF mutations. The gene discussed is KRAS; the disease is colorectal cancer.